Matthias T.
- Country
- Germany
- Department
- Klinik und Poliklinik für Innere Medizin II
Research Overview
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Study Evaluating Efficacy and Safety of JNJ‑78934804 Combination Therapy versus Guselkumab in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Trial of JNJ‑78934804 Combination Therapy vs Guselkumab in Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 210 of 329 partner sites.
Specializations
Inflammatory Bowel Disease Research
This investigator specializes in the treatment of moderately to severely active ulcerative colitis, focusing on innovative therapeutic approaches for managing inflammatory bowel conditions.
- Novel biological therapies
- Treatment-resistant UC cases
- Disease activity monitoring
Particular interest in evaluating new therapeutic agents for achieving clinical remission in UC patients.
Immunotherapy Development
Expertise in studying advanced immunological treatments, including the evaluation of monoclonal antibodies and novel biological compounds for inflammatory conditions.
- Biological therapy assessment
- Comparative treatment efficacy
- Long-term therapeutic outcomes
Focus on investigating both intravenous and subcutaneous administration routes for biological treatments.
Clinical Therapeutics
Specialized in endoscopic improvement assessment and the evaluation of symptomatic remission in inflammatory bowel conditions.
- Treatment safety profiles
- Long-term disease management
- Therapeutic maintenance strategies
Dedicated to investigating extended treatment protocols and maintenance therapy approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.